A young man, age nineteen, in his second year of college, develops increasing social withdrawal over months. His family notices he has stopped showering. He spends hours alone in his room. Then, over a few weeks, he begins to report that the television is sending him messages, that his roommate is trying to poison him, that he can hear his mother's voice when she is not there. What is happening?
In one influential model, his mesolimbic dopamine system has become dysregulated. The VTA-to-accumbens pathway is firing aberrantly, attaching salience — this matters, this means something — to stimuli that are random or innocuous. The TV becomes meaningful. The roommate becomes suspicious. Internal voices — perhaps misattributed inner speech — become external and meaningful. This is the aberrant salience hypothesis of psychosis, developed by Shitij Kapur and others.
Meanwhile, his mesocortical dopamine pathway is hypoactive. The VTA-to-PFC projection is firing less. His prefrontal cortex is starved of the dopamine it needs to maintain working memory, cognitive control, and signal-to-noise. He cannot think clearly. He cannot suppress intrusive thoughts. He cannot integrate new evidence to update his false beliefs. This is part of why patients in active psychosis often cannot simply reason their way out of it — the cognitive system needed for such reasoning is itself compromised.
He is started on risperidone, a second-generation antipsychotic. It blocks D2 receptors in the mesolimbic pathway, reducing the aberrant salience signal. The voices fade. The paranoid ideas loosen. Over weeks, his thinking organizes. He begins to recognize that his earlier beliefs were not accurate.
But there are costs. He gains weight — fifteen pounds in three months. His fasting glucose creeps up. His triglycerides rise. He develops mild dyslipidemia and prediabetes. The same medication that calmed his mesolimbic circuit has, through D2 blockade in the hypothalamic appetite centers, through H1 antihistamine effects on satiety, through 5-HT2C effects on metabolism, perturbed his metabolic homeostasis. This is the trade-off of antipsychotic therapy, and it is why metabolic monitoring (weight, lipids, glucose, A1c) is essential at baseline, three months, and then every six months.
His PFC dopamine, already low, is now lower from the additional D2 blockade. His negative and cognitive symptoms — the social withdrawal, the flat affect, the difficulty thinking clearly — improve only partially. The positive symptoms are gone, but he is not the same young man he was a year ago. Some of this is the residual cognitive cost of the medication. Some is the residual effect of the disease itself. Distinguishing the two is one of the central clinical challenges in schizophrenia.
The treatment plan from here involves continued antipsychotic medication (relapse is common if stopped prematurely, particularly in the first two years after onset), psychotherapy (CBT for psychosis can help with persistent symptoms), social support (family psychoeducation reduces relapse), and gradual reintegration into school, work, or social life. Metabolic monitoring continues. Adjunct medications for the metabolic side effects may be needed (metformin, statins) depending on trajectory.
Notice that this scenario integrates the VTA, the nucleus accumbens, the prefrontal cortex, dopamine receptors, the metabolic axes, and a specific theoretical framework, the aberrant salience hypothesis. We are now thinking at the level of systems, not facts. The patient in your office is not a list of symptoms — they are this circuit, dysregulated in this particular way, responding to this molecular intervention with these particular costs and benefits.
That is the goal of the whole audiobook. When you next see a young person with first-episode psychosis, you should be able to see them not just as a clinical presentation but as a system, with specific circuits failing in specific ways, and specific interventions you can offer that address those circuits while accepting the costs that those interventions impose.